and Oteseconazole, used to treat fungal infections in females. G 2 Retro was able to correctly generate exactly the same patented synthesis routes for these medicines, and provided alternative ...

and Oteseconazole, used to treat fungal infections in females. G 2 Retro was able to correctly generate exactly the same patented synthesis routes for these medicines, and provided alternative ...

A phase 3 randomized, double-blind, controlled trial has shown that oteseconazole (Mycovia Pharmaceuticals), an oral antifungal agent, is safe and effective in treating acute and recurrent yeast ...

Credit: Getty Images. Oteseconazole is a novel oral inhibitor of fungal CYP51. Topline results were announced from two phase 3 trials evaluating oteseconazole (VT-1161; Mycovia Pharmaceuticals ...

DURHAM, N.C.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) approved VIVJOA™ (oteseconazole capsules), an azole antifungal indicated to reduce the incidence of recurrent ...

About VIVJOA™ VIVJOA™ (oteseconazole) capsules are an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for oteseconazole for the treatment of recurrent vulvovaginal candidiasis (VVC). Results from ...

Oteseconazole is designed to selectively inhibit fungal CYP51, which is required for fungal cell wall integrity. Due to its chemical structure, oteseconazole has a lower affinity for human CYP ...